Navigation Links
Helix BioPharma Corp. Announces Fiscal Q1 2010 Results
Date:12/9/2009

; the timing of completion of the Phase II pharmacokinetic study of Topical Interferon Alpha-2b for the minimum 12 patients; sufficiency of the Company's cash reserves and expected cash flow from operations; and other information in future periods, which statements can be identified by the use of forward-looking terminology such as "plans", "project", "expected", "intends"; "next", "anticipated", "developing", "will" or variations thereon. Although Helix believes that the expectations reflected in such forward-looking statements are reasonable, such statements and information involve risks and uncertainties, and undue reliance should not be placed on such statements. Forward-looking statements, including financial outlooks, are intended to provide information about management's current plans and expectations regarding future operations, including without limitation, future financing requirements, and may not be appropriate for other purposes. Certain material factors or assumptions have been applied in making forward-looking statements, including, but not limited to, assumptions regarding the patient recruitment rate for the ongoing Phase II pharmacokinetic study for Topical Interferon Alpha-2b (cervical dysplasia) and the sufficiency of data from the minimum 12 patients; the timely and successful completion of all activities leading up to the Company's planned IND and CTA filings for both L-DOS47 and Topical Interferon Alpha-2b (cervical dysplasia), including without limitation, GMP manufacturing; the timely provision of services and supplies by third parties; future revenue and costs; and the receipt of required regulatory approvals and necessary financing. Important risk factors that could cause actual results to differ materially from these forward-looking statements include, without limitation, the Company's continuing need for additional capital, which may not be available in a timely manner or at all and which if not obtained will have a material adverse imp
'/>"/>
SOURCE Helix BioPharma Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. Helix Receives Approval to Open Sites in Germany for its Ongoing Clinical Trial With Topical Interferon Alpha-2b in Patients With Ano-Genital Warts
2. J. Craig Venter, Ph.D. Receives Double Helix Medal from Cold Spring Harbor Laboratory
3. Helix BioPharma Provides Updates on Topical Interferon Alpha-2b and L-DOS47 Following Pre-IND Meetings With the U.S. FDA
4. Helix BioPharma Corp. Announces Fiscal 2009 Results
5. Helix BioPharma Corp. Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha-2b in Patients With Ano-Genital Warts
6. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
7. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
8. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
9. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
10. Morria Biopharmaceuticals Plc Initiates Phase I Clinical Study of MRX-4 in Allergic Rhinitis
11. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... 2015   Prime Therapeutics LLC (Prime), a ... members, today released the following statement responding to the ... first biosimilar to enter the U.S. market. ... of Sandoz,s Zarxio® to treat neutropenia, a condition affecting ... milestone in our country,s journey to curb the escalating ...
(Date:3/6/2015)... Solutions, Inc. (Pink Sheets: ASDS ) ("Ascendant" ... fourth quarter and year ended December 31, 2014. The ... than $0.01 per share, on revenues of $8,018,000 for ... net income of $195,000, or $0.01 per share, on ... The substantial increase in fourth quarter 2014 revenue was ...
(Date:3/6/2015)... TAMPA, Fla. , March 6, 2015 /PRNewswire/ ... received special validation from Intuitive Surgical, the manufacturer ... for their Triton-36 Instrument Cleaning System. This approval ... highest standards in cleanliness currently in place for ... this special validation for reprocessing robotic surgical instruments ...
Breaking Medicine Technology:Prime Therapeutics welcomes FDA's approval of first biosimilar in U.S., but says more clarity is needed 2Prime Therapeutics welcomes FDA's approval of first biosimilar in U.S., but says more clarity is needed 3Ascendant Solutions, Inc. Reports Fourth Quarter and Year End 2014 Earnings 2Ascendant Solutions, Inc. Reports Fourth Quarter and Year End 2014 Earnings 3Ascendant Solutions, Inc. Reports Fourth Quarter and Year End 2014 Earnings 4Ascendant Solutions, Inc. Reports Fourth Quarter and Year End 2014 Earnings 5Ultra Clean Systems Reaches Exclusive Place within Robotic Surgical Instrument Cleaning Industry with Latest Certifications 2
... Inc. (Nasdaq: ENZN) announced today that four,posters containing ... Meeting of the American Association for Cancer Research,(AACR) ... 2007 in Los Angeles, CA., Details of the ... EZN-2208, a novel polyethyleneglycol-SN38,conjugate, has potent antitumor activity ...
... 13, 2007 - Point Therapeutics, Inc.,(NASDAQ: POTP) today ... 2007 Annual Meeting of the American,Association for Cancer ... 14-18, 2007. The AACR poster presentations report,on preclinical ... details for the AACR presentations are as,follows: , ...
Cached Medicine Technology:Enzon to Present Preclinical Data From PEG-SN38 and PEGylation,Technology Studies at AACR Meeting 2
(Date:3/6/2015)... 06, 2015 Follow us on ... most common forms of cancer and is the leading ... be screened through various techniques and tools, including mammography, ... the gold standard technique in breast cancer screening, driven ... taken for the procedure, required expertise to carry out ...
(Date:3/6/2015)... “On Tap” takes the audience on a journey ... the silver screen and to modern day rhythm tap. ... their famous eye-high kicks! Producers, directors and choreographers Mary Six ... dancing in this robust show, showcasing one of the only ... , “On Tap” is proud to host guest stars ...
(Date:3/6/2015)... 2015 As the Association of ... of 90,000 doctors by 2025 is updated this week ... (SH) is proactively preparing by analyzing demographics and pursuing ... , Several factors including the increasing number of ... under the Affordable Care Act and an uneven distribution ...
(Date:3/6/2015)... 2015 Jvion, the Atlanta-based leader ... a Clostridium Difficile (C Diff) predictive use case ... use case is the latest in a broad ... infections, chronic conditions, and individual illnesses. Using the ... solution flags at risk individuals to help support ...
(Date:3/6/2015)... Yisrayl Hawkins, Pastor and Overseer of ... a new publication explaining how micro-kingdoms keep the earth ... article titled “Microorganisms Do Much More Than You Think” ... were created and designed to keep all things functioning ... the functions of these micro-kingdom, but does not realize ...
Breaking Medicine News(10 mins):Health News:Rising Popularity of 3D Mammography Drives the Global Mammography Equipment Market, According to a New Report by Global Industry Analysts, Inc. 2Health News:Rising Popularity of 3D Mammography Drives the Global Mammography Equipment Market, According to a New Report by Global Industry Analysts, Inc. 3Health News:The Legacy Dancers, a Dazzling Dance Troupe of Former Rockettes, Kick to New Heights in “On Tap: From Broadway to the Silver Screen” 2Health News:Susquehanna Health Plans Progressively to Prevent Projected Physician Shortfall 2Health News:Susquehanna Health Plans Progressively to Prevent Projected Physician Shortfall 3Health News:Susquehanna Health Plans Progressively to Prevent Projected Physician Shortfall 4Health News:Jvion Predicts Patients at Risk of C Difficile Infection to Reduce Risk and Save Lives 2Health News:Yisrayl Hawkins Tells Scientists Exactly What Makes Life Function Properly in New Publication 2
... which is angered by the defence attorneys of the AIIMS ... about the case where a boy, suffering from cancer, got ... 2001. ,The victim, who was nine years ... in July 2000 for treatment of cancer, supposedly has contracted ...
... the Human Fertilization and Embryology Authority show that recently ... opting for assisted reproduction technology// (ART) in the UK. ... of these women is 34. There is increase in ... for infertility. The doctors and scientists say that there ...
... new study, the antidepressant drug Zoloft (sertraline) may avoid ... also increase// the time interval between the depressive episodes. ... to background information in the study, reports foodconsumer.org. ... of age, who had recovered from depression during treatment ...
... the UK have been busy. They have tolled up 100,000 ... stop and control the spread of bird flu.// Researchers eleven ... they screened possible drug components that could be effective against ... the UK was originally built to help particle physicists examine ...
... A recent conducted at University of Michigan Health Systems ... have greater expectations of doom from their screening //mammography ... than not these expectations were unusually high or unrealistic. ... to an outpatient clinic for screening mammography. The participants ...
... the oldest mother in UK, from Lewes in East Sussex, ... fertility treatment. She gave the statement that this child had ... John Farrant made a joint statement, "We wish to emphasise ... without courage. A great deal of thought has been given ...
Cached Medicine News:Health News:A Boy Undergoing Treatment For Cancer Gets AIDS At AIIMS 2Health News:UK Computer Grid In Bird Flu Fight 2Health News:UK Computer Grid In Bird Flu Fight 3Health News:Most Women Have Unrealistic Expectations From Screening Mammography 2Health News:A mother at 63: oldest in UK! 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: